ArticleMolecular neurobiology2019
Targeting CB
Open access · greenAbstract read
In one paragraph
Article in Molecular neurobiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
3.4field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 34 citations in OpenAlex.
- Targeting GPCR Signaling in Parkinson's Disease: From Molecular Pathology to Exercise-Based Therapeutics.Molecular neurobiology · 2026Review
- Neuroprotective Role of Cannabinoid CBMolecular neurobiology · 2026Article
- Ageing, Neurodegeneration and the Endocannabinoid System.Current topics in behavioral neurosciences · 2026Review
- Coactivation of CB1 and GPR55 promotes GABA release and motor behavior at striatonigral terminals through increased dimerization induced by CB1 activation.Frontiers in molecular neuroscience · 2026Article
- Evaluating the Antitumor Potential of Cannabichromene, Cannabigerol, and Related Compounds fromInternational journal of molecular sciences · 2025Article
- Potential Protective Effects of Pungent Flavor Components in Neurodegenerative Diseases.Molecules (Basel, Switzerland) · 2024Review
- Modulation of neuroinflammation and oxidative stress by targeting GPR55 - new approaches in the treatment of psychiatric disorders.Molecular psychiatry · 2024Review
- From Classical to Alternative Pathways of 2-Arachidonoylglycerol Synthesis: AlterAGs at the Crossroad of Endocannabinoid and Lysophospholipid Signaling.Molecules (Basel, Switzerland) · 2024Review
- Heteromers Formed by GPR55 and Either Cannabinoid CBInternational journal of molecular sciences · 2024Article
- Neuroprotection afforded by targeting G protein-coupled receptors in heteromers and by heteromer-selective drugs.Frontiers in pharmacology · 2023Review
- Regulation of Expression of Cannabinoid CBInternational journal of molecular sciences · 2022Article
- Roles of the Cannabinoid System in the Basal Ganglia in Parkinson's Disease.Frontiers in cellular neuroscience · 2022Review
- The Binding Mode to Orthosteric Sites and/or Exosites Underlies the Therapeutic Potential of Drugs Targeting Cannabinoid CBFrontiers in pharmacology · 2022Review
- Intrapallidal injection of cannabidiol or a selective GPR55 antagonist decreases motor asymmetry and improves fine motor skills in hemiparkinsonian rats.Frontiers in pharmacology · 2022Article
- Preclinical Investigation in Neuroprotective Effects of the GPR55 Ligand VCE-006.1 in Experimental Models of Parkinson's Disease and Amyotrophic Lateral Sclerosis.Molecules (Basel, Switzerland) · 2021Article
- BiP Heterozigosity Aggravates Pathological Deterioration in Experimental Amyotrophic Lateral Sclerosis.International journal of molecular sciences · 2021Article
- Cuprizone-Induced Neurotoxicity in Human Neural Cell Lines Is Mediated by a Reversible Mitochondrial Dysfunction: Relevance for Demyelination Models.Brain sciences · 2021Article
- Current Aspects of the Endocannabinoid System and Targeted THC and CBD Phytocannabinoids as Potential Therapeutics for Parkinson's and Alzheimer's Diseases: a Review.Molecular neurobiology · 2020Review
- Potential application of endocannabinoid system agents in neuropsychiatric and neurodegenerative diseases-focusing on FAAH/MAGL inhibitors.Acta pharmacologica Sinica · 2020Review
- Distinctive Evidence Involved in the Role of Endocannabinoid Signalling in Parkinson's Disease: A Perspective on Associated Therapeutic Interventions.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Eva Martínez-PinillaDepartamento de Morfología y Biología Celular, Facultad de Medicina, Universidad de Oviedo, Julián Clavería s/n, 33006, Oviedo, Asturias, Spain. martinezpinillaeva@gmail.com.ORCID http://orcid.org/0000-0002-0572-0926
David AguinagaMolecular Neurobiology Laboratory, Department of Biochemistry and Molecular Biomedicine, Faculty of Biology, University of Barcelona, Diagonal 643, Prevosti Building, 08028, Barcelona, Spain.
Gemma NavarroInstitut de Biomedicina de la Universitat de Barcelona. IBUB, Barcelona, Spain.
Alberto J RicoCentro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.
Julen OyarzábalSmall Molecule Discovery Platform, Molecular Therapeutics Program, Centre for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.
Juan A Sánchez-AriasSmall Molecule Discovery Platform, Molecular Therapeutics Program, Centre for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.
José Luis LanciegoCentro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain. jlanciego@unav.es.
Rafael FrancoMolecular Neurobiology Laboratory, Department of Biochemistry and Molecular Biomedicine, Faculty of Biology, University of Barcelona, Diagonal 643, Prevosti Building, 08028, Barcelona, Spain. rfranco@ub.edu.
Instituto de Salud Carlos III · ESUniversidad de Navarra · ESUniversidad de Oviedo · ES
Funding
Fundació la Marató de TV3 20141330 and 20141331
Abstract
Cannabinoid CB
Indexed as
Molecular Targeted TherapyCell Line, TumorHumansLigandsModels, BiologicalNeuroprotectionNeuroprotective AgentsOxygen ConsumptionParkinson DiseaseReceptor, Cannabinoid, CB1Receptors, CannabinoidGPR55 protein, humanLigandsNeuroprotective AgentsReceptor, Cannabinoid, CB1Receptors, CannabinoidCannabinoid receptorsGPCRsMPP+Neurodegenerative diseasesNeuroprotection
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.